Skip to content
Tenfell
Awarded contract
Published 13 Feb 2020

NHS Midlands and East Branded Medicines - Tranche A

NHS England · London

Key facts

Awarded
15 Jan 2020
Contract starts
01 Mar 2020
Contract ends
28 Feb 2022
Procedure
Open procedure (above threshold)
Buyer type
Central government

Awarded to 27 suppliers

SupplierValue
Takeda UK Limited—
Janssen-Cilag Ltd—
Pfizer Ltd—
Teva UK Ltd—
MSD—
Amgen Ltd—
Chugai Pharma Uk Ltd—
Napp Pharmaceuticals—
Sandoz Ltd—
Accord-UK Ltd—
Biogen—
Celltrion Healthcare United Kingdom Limited—
Eli Lilly & Company Ltd—
Gilead Sciences Limited—
Ipsen—
Merck Serono Limited—
Novo Nordisk—
Roche Products Ltd—
UCB Pharma Ltd—
ViiV Healthcare UK Ltd—
Intrapharm Laboratories Ltd—
Ferring Pharmaceuticals Limited—
Pharmacosmos UK Ltd—
Vifor Pharma UK Limited—
Bristol-Myers Squibb Pharmaceuticals Ltd—
Allergan Limited—
Merz Pharma UK Ltd—

Description

NHS Framework for the Midlands and East, Branded Medicines - Tranche A plus Cytokine Modulators and other Monoclonal Antibodies.

Offer reference number: CM/PHR/16/5525

CM/PHR/16/5525/01 - NHS Framework for the Midlands and East, Branded Medicines - Tranche A, Period of framework: 1 March 2020 to 28 February 2022 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/16/5525/02 - NHS Framework for the Midlands and East Branded Medicines - Cytokine Modulators and other monoclonal Antibodies, Period of framework: 1 March 2020 to 28 February 2021 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.